Total Funding
44
40
Total FundingPost-IPO Equity raised
Growth Score
-4 pts
Heat Score
1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
92471
Lipella Pharmaceuticals is a biotechnology company that develops products for intravesical therapy.
Jonathan Kaufman: CEO and Co-founderPast Role: MetriTrack, Chief Financial Officer
Michael Chancellor: Co-founder, Chief Medical Officer
About the Company
Lipella Pharmaceuticals is a biotechnology company that develops products for intravesical therapy. It is a method of providing local treatments directly to the urinary bladder lumen via urethral catheterization. Indications they target include interstitial cystitis (also known as painful bladder syndrome), overactive bladder, and superficial
bladder cancer.
Interstitial cystitis is a chronic, painful, inflammatory condition of the bladder wall that affects over 1 million people in the United States. Its cause is unknown and there is no cure. Treatment options exist, but a majority of cases are refractive to existing therapies.
